Congenital Adrenal Hyperplasia Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The congenital adrenal hyperplasia treatment market size is expected to grow from USD 418.12 million in 2025 to USD 446.38 million in 2026 and is forecast to reach USD 619.09 million by 2031 at 6.76% CAGR over 2026-2031. This report is segmented by Disease Type (Classic, Nonclassic), Drug Class (Glucocorticoids, Mineralocorticoids, and More), Route of Administration (Oral, Injectable, Other), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Congenital Adrenal Hyperplasia Treatment Market Trends and Insights

Approval of a Nonsteroidal Adjunctive Therapy

The FDA approved CRENESSITY, or crinecerfont, in December 2024 for children and adults with classic congenital adrenal hyperplasia. As a CRF1 receptor antagonist, it suppresses pituitary ACTH secretion and downstream adrenal androgen production. This mechanism allows clinicians to reduce glucocorticoid doses toward a physiological range while maintaining disease control. In the Phase 3 CAHtalyst program, 63% of adults receiving crinecerfont reached physiological glucocorticoid dosing with maintained or improved androstenedione control, compared with 18% receiving placebo. CRENESSITY generated USD 301.2 million in net product sales during 2025, its first full year of commercialization. The congenital adrenal hyperplasia treatment market is gaining a new treatment standard as prescribers consider lower steroid exposure a practical clinical goal rather than a limited aspiration.

Expansion of Newborn Screening Programs and Diagnostic Profiling

Systematic measurement of 17-hydroxyprogesterone in newborn dried blood spots remains central to identifying classic congenital adrenal hyperplasia before adrenal crisis occurs. Turkey’s nationwide program found that secondary LC-MS/MS confirmation could reduce false-positive results by up to 95% compared with immunoassay alone. Armenia began a screening pilot in Yerevan in April 2024 and identified 4 classic cases among 16,168 screened newborns before extending the program nationally in April 2025. A Chinese prospective study covering 21,239 newborns showed that long-read sequencing could characterize CYP21A2 variant severity and reduce false-positive findings. These screening and profiling approaches shorten the path from suspicion to diagnosis and guide the intensity of follow-up care. They also enlarge the future treated population for the congenital adrenal hyperplasia treatment market by converting previously undiagnosed cases into patients requiring lifelong management.

Lifelong Cost Burden of Hormone Replacement

Patients with congenital adrenal hyperplasia require uninterrupted hormone replacement from birth, which creates a persistent financial burden. Generic hydrocortisone is available from multiple suppliers, but modified-release therapies and newer adjunctive medicines carry higher prices. Neurocrine’s support program seeks to reduce eligible U.S. patients’ CRENESSITY out-of-pocket cost to USD 10 or less per month, and 2,048 new patient enrollment forms were submitted in 2025. Reimbursement reviews outside the United States can be more difficult because national coverage and pricing standards vary substantially. In emerging economies, even generic hydrocortisone can create a recurring household expense when rare-disease reimbursement is unavailable. These conditions slow the uptake of higher-priced treatments in the congenital adrenal hyperplasia treatment market, even after regulatory authorization.

Other drivers and restraints analyzed in the detailed report include:

• Demand for Physiological Glucocorticoid Replacement
• Asia-Pacific Specialty-Care Expansion and Evidence Development
• Narrow Dosing Window and Limited Specialist Monitoring

Segment Analysis

Classic congenital adrenal hyperplasia held 69.31% of revenue in 2025, making it the foundation of the congenital adrenal hyperplasia treatment market. Salt-wasting and simple-virilizing forms require sustained glucocorticoid treatment and, for salt-wasting disease, mineralocorticoid replacement. These subtypes account for 90% to 95% of classic cases caused by CYP21A2 mutations. Their need for treatment from infancy produces a stable prescription base across glucocorticoids, mineralocorticoids, and adjunctive therapies. CRENESSITY is approved for classic congenital adrenal hyperplasia in patients aged 4 years and older. Its use adds a premium adjunctive layer without removing the underlying need for cortisol and, where relevant, aldosterone replacement.

Nonclassic congenital adrenal hyperplasia is forecast to grow at an 8.58% CAGR through 2031. The condition can present as premature pubarche, acne, polycystic ovarian morphology, or subfertility, which has led to underdiagnosis or confusion with other hyperandrogenic conditions. LC-MS/MS steroid ratio testing allows adult endocrinology and reproductive medicine clinics to distinguish nonclassic disease from polycystic ovary syndrome and idiopathic hyperandrogenism. More accurate testing is bringing a previously unmanaged patient group into structured pharmacological care. Reproductive endocrinologists are therefore becoming a more relevant prescriber group alongside pediatric endocrinologists. This broader referral base supports the congenital adrenal hyperplasia treatment industry as diagnosis becomes more consistent in adolescent and adult care.

Glucocorticoids accounted for 60.24% of the congenital adrenal hyperplasia treatment market size in 2025. They remain essential because no approved or pipeline therapy is intended to eliminate cortisol replacement. Hydrocortisone, prednisolone, and dexamethasone serve patients with different age, growth, severity, and adherence needs. Generic availability from suppliers including Teva, Hikma, and Sandoz supports access across high-income and emerging economies. Mineralocorticoids, principally fludrocortisone, remain necessary for patients with salt-wasting classic disease. Their role is supported by consistent guideline recommendations for aldosterone replacement in this subtype.

CRF1 and ACTH pathway inhibitors are forecast to grow at a 10.22% CAGR through 2031. The rate reflects the commercial rollout of crinecerfont and the progress of new MC2R-targeted candidates. Crinetics initiated the adult CALM-CAH Phase 3 trial for atumelnant in December 2025. It initiated the BALANCE-CAH Phase 2/3 pediatric trial in January 2026. Phase 2 results showed rapid, sustained, and statistically significant reductions in androstenedione and 17-hydroxyprogesterone. Neurocrine also licensed SCO-483, now NBI-1852737, in April 2026, showing that its congenital adrenal hyperplasia treatment industry strategy extends beyond a single product.

Complete Report Scope:

• By Disease Type
  • Classic Congenital Adrenal Hyperplasia
  • Nonclassic Congenital Adrenal Hyperplasia
• By Drug Class
  • Glucocorticoids
  • Mineralocorticoids
  • CRF1 and ACTH Pathway Inhibitors
  • Other Drug Classes
• By Route of Administration
  • Oral
  • Injectable
  • Other Routes of Administration
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 46.61% of the congenital adrenal hyperplasia treatment market share in 2025. The United States has the most developed branded adjunctive treatment setting following the December 2024 FDA approval and commercial launch of CRENESSITY. CRENESSITY generated USD 301.2 million in U.S. net product sales during 2025, including USD 135.3 million in the fourth quarter. More than 80% of dispensed prescriptions had reimbursement coverage by year-end. The United States has an estimated 40,000 patients with classic disease, while only 10% had received crinecerfont by the end of 2025. Canada and Mexico have established newborn screening programs, with Mexico expanding coverage in rural areas through federal child health programs.

Europe is the second-largest geographic area for the congenital adrenal hyperplasia treatment market. Its position reflects established rare-disease regulatory processes, national reimbursement reviews, and specialist centers contributing to the International I-CAH Registry across 33 centers in 19 countries. Germany, the United Kingdom, France, Italy, and Spain form the regional revenue base. The United Kingdom and Germany have advanced adoption of Efmody for patients aged 12 years and older and adults. The CaHASE2 study documented the continuing burden of suboptimal outcomes in specialist care, which adds to the evidence base for adjunctive treatments. Northern Spain has tested a two-tier LC-MS/MS newborn screening approach that reduced false-positive results without reducing sensitivity. European access to crinecerfont will depend on EMA review and country-level health technology assessment decisions.

Asia-Pacific is projected to grow at an 8.25% CAGR through 2031, the fastest regional rate in the congenital adrenal hyperplasia treatment market. Japan combines comprehensive rare-disease reimbursement with government support for drug development and has become both a prescribing center and a source of therapeutic innovation. China’s 2026 clinical management guidelines for 21-hydroxylase deficiency support more consistent diagnosis and treatment practices. India has a meaningful diagnostic gap, as screening coverage remains uneven despite a large number of annual births. GCC countries provide the main care base in the Middle East and Africa through centralized specialty hospitals, while South Africa leads sub-Saharan African care. Brazil and Argentina are expanding public screening in South America, although prolonged reimbursement reviews limit near-term branded therapy access. The congenital adrenal hyperplasia treatment market has an opportunity to translate regional screening gains into regular specialist follow-up and earlier initiation of appropriate therapy.

List of Companies Covered in this Report:

• Abbvie
• Adrenas Therapeutics, Inc.
• AdvaCare
• BridgeBio Pharma, Inc.
• Crinetics Pharmaceuticals, Inc.
• Diurnal Limited
• Eton Pharmaceuticals, Inc.
• Hikma Pharmaceuticals
• Merck
• Millendo Therapeutics, Inc.
• Neurocrine Biosciences
• Novartis
• Pfizer
• Sandoz Group AG
• Sanofi
• Spruce Biosciences, Inc.
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support